Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (201-210 of 567) with videos related to

Pageof 57
Sort By:
The American Journal of Cardiology|March 15, 1995
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trialD J Moliterno, R M Califf, F V Aguirre, et al.
The American Journal of Cardiology|November 1, 1986
Medical, psychological and social correlates of work disability among men with coronary artery diseaseM A Hlatky, T Haney, J C Barefoot, et al.
Pharmacoeconomics|August 18, 2000
Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndromeE L Eisenstein, E D Peterson, J G Jollis, et al.
Annals of Internal Medicine|December 1, 1996
Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I InvestigatorsP E Aylward, R G Wilcox, J H Horgan, et al.
American Heart Journal|December 2, 2000
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experienceC K Wong, H D White, R G Wilcox, et al.
Thrombosis and Haemostasis|March 2, 1992
Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosisT L Ortel, J P Gockerman, R M Califf, et al.
Clinical Pharmacology and Therapeutics|June 13, 2008
Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysisJ S Li, C M Baker-Smith, P B Smith, et al.
American Heart Journal|January 30, 1999
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC InvestigatorsM C Thel, R M Califf, J E Tcheng, et al.
Journal of the American College of Cardiology|July 1, 1995
Percutaneous revascularization of chronic coronary occlusions: an overviewJ A Puma, M H Sketch, J E Tcheng, et al.
Journal of Women'S Health|June 1, 1997
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesE K Moen, C R Asher, D P Miller, et al.
Pageof 57

Showing results (201-210 of 567) with videos related to

Sort By:
Pageof 57
The American Journal of Cardiology|March 15, 1995
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trialD J Moliterno, R M Califf, F V Aguirre, et al.
The American Journal of Cardiology|November 1, 1986
Medical, psychological and social correlates of work disability among men with coronary artery diseaseM A Hlatky, T Haney, J C Barefoot, et al.
Pharmacoeconomics|August 18, 2000
Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndromeE L Eisenstein, E D Peterson, J G Jollis, et al.
Annals of Internal Medicine|December 1, 1996
Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I InvestigatorsP E Aylward, R G Wilcox, J H Horgan, et al.
American Heart Journal|December 2, 2000
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experienceC K Wong, H D White, R G Wilcox, et al.
Thrombosis and Haemostasis|March 2, 1992
Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosisT L Ortel, J P Gockerman, R M Califf, et al.
Clinical Pharmacology and Therapeutics|June 13, 2008
Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysisJ S Li, C M Baker-Smith, P B Smith, et al.
American Heart Journal|January 30, 1999
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC InvestigatorsM C Thel, R M Califf, J E Tcheng, et al.
Journal of the American College of Cardiology|July 1, 1995
Percutaneous revascularization of chronic coronary occlusions: an overviewJ A Puma, M H Sketch, J E Tcheng, et al.
Journal of Women'S Health|June 1, 1997
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesE K Moen, C R Asher, D P Miller, et al.
Pageof 57